How many clinical trials are tracked for Glaucoma?

157 trials are tracked, 7 with published results.

Glaucoma Research

Glaucoma: what the trials found

Several fixed-dose combinations and individual agents have been evaluated for intraocular pressure (IOP) management. Netarsudil/latanoprost combination showed mean reductions in IOP of 15.7% to 21.2% at week 12 ⁸. Brinzolamide/brimonidine tartrate suspension demonstrated significant reductions in IOP across various time points throughout the day ¹³, while Cosopt (dorzolamide/timolol) and Combigan were also utilized in established clinical contexts [14, 11, 22].

The impact of various treatments on ocular surface health and side effects is documented. Bimatoprost 0.01% was associated with a 33.3% to 37.7% rate of treatment-related ocular surface adverse events ¹², while Travoprost showed varying rates of ocular hyperemia and corneal staining over time ²⁰. Xalatan was associated with significant changes in Tear Break up Time (TBUT) ⁷. Additionally, periocular skin hyperpigmentation was not significantly different across latanoprost, bimatoprost, and travoprost treatments over a one-year period ¹⁷.

Surgical and adjunctive interventions also contribute to management. Trabeculectomy with preoperative Diamox/DexaEDO treatment resulted in mean IOP changes of 8.12 to 8.30 three months post-procedure ¹⁶. Bevacizumab was shown to result in significant reductions in intraocular pressure ⁹.

Individual variability in physiological responses is established; studies showed significant variations between individuals regarding eye pressure response to timolol and latanoprost, as well as differences in aqueous flow and episcleral venous pressure ⁶.

For the clinician treating this condition

Fixed combinations like Netarsudil/latanoprost and Brinzolamide/brimonidine provide measurable reductions in IOP [8, 13].
Clinical management must account for significant individual variability in aqueous flow and pressure responses to standard medications like timolol and latanoprost ⁶.
Long-term monitoring of the ocular surface is relevant as treatments such as bimatoprost can lead to reported adverse events [12, 20].

AI synthesis of 12 cited trials, updated Jun 23, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.